Clinical Trial Update: Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial [Phase 4]

View source ↗

Summary

Phase 4 trial update showing completion of a study of oral nilotinib (AMN107) in adults with imatinib-resistant or intolerant chronic myeloid leukemia across bl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia | Phase 4 | Status: COMPLETED